Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review

Introduction Inotuzumab ozogamicin(InO) is indicated for the treatment of adults with relapsed or refractory(R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes bybaseline characteristics for patients with R/R ALL treated with InO to identifywhich patients may benefit most.